- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1366KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 115KB)
Decitabine + cedazuridine – March 2021
Decitabine and cedazuridine: Tablet containing decitabine 35 mg + cedazuridine 100 mg; Inqovi®
Last updated
16 July 2021